JAK Inhibitors in the Management of Dermatologic Disorders: Clinical Implications of the Latest Safety Findings

What this episode covers

Visit https://www.peervoice.com/PDW860 to view the entire programme with slides. After completing “JAK Inhibitors in the Management of Dermatologic Disorders: Clinical Implications of the Latest Safety Findings”, participants will be able to: Describe the patient demographics in the safety studies for Janus kinase (JAK) inhibitors; Summarise key safety data for approved and emerging JAK inhibitors in patients with atopic dermatitis (AD) or alopecia areata (AA); Use clinical and patient characteristics in the context of AD or AA to determine appropriate benefit and risk profiles when considering the use of a JAK inhibitor.

Distinct summary based on available episode metadata or transcript content.